Cargando…

Hybrid cis-stilbene Molecules: Novel Anticancer Agents

The growing interest in anticancer hybrids in the last few years has resulted in a great number of reports on hybrid design, synthesis and bioevaluation. Many novel multi-target-directed drug candidates were synthesized, and their biological activities were evaluated. For the design of anticancer hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Piekuś-Słomka, Natalia, Mikstacka, Renata, Ronowicz, Joanna, Sobiak, Stanisław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471163/
https://www.ncbi.nlm.nih.gov/pubmed/30875859
http://dx.doi.org/10.3390/ijms20061300
_version_ 1783411965518938112
author Piekuś-Słomka, Natalia
Mikstacka, Renata
Ronowicz, Joanna
Sobiak, Stanisław
author_facet Piekuś-Słomka, Natalia
Mikstacka, Renata
Ronowicz, Joanna
Sobiak, Stanisław
author_sort Piekuś-Słomka, Natalia
collection PubMed
description The growing interest in anticancer hybrids in the last few years has resulted in a great number of reports on hybrid design, synthesis and bioevaluation. Many novel multi-target-directed drug candidates were synthesized, and their biological activities were evaluated. For the design of anticancer hybrid compounds, the molecules of stilbenes, aromatic quinones, and heterocycles (benzimidazole, imidazole, pyrimidine, pyridine, pyrazole, quinoline, quinazoline) were applied. A distinct group of hybrids comprises the molecules built with natural compounds: Resveratrol, curcumin, coumarin, and oleanolic acid. In this review, we present the studies on bioactive hybrid molecules of a well-known tubulin polymerization inhibitor, combretastatin A-4 and its analogs with other pharmacologically active entities. The mechanism of anticancer activity of selected hybrids is discussed considering the structure-activity relationship.
format Online
Article
Text
id pubmed-6471163
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64711632019-04-26 Hybrid cis-stilbene Molecules: Novel Anticancer Agents Piekuś-Słomka, Natalia Mikstacka, Renata Ronowicz, Joanna Sobiak, Stanisław Int J Mol Sci Review The growing interest in anticancer hybrids in the last few years has resulted in a great number of reports on hybrid design, synthesis and bioevaluation. Many novel multi-target-directed drug candidates were synthesized, and their biological activities were evaluated. For the design of anticancer hybrid compounds, the molecules of stilbenes, aromatic quinones, and heterocycles (benzimidazole, imidazole, pyrimidine, pyridine, pyrazole, quinoline, quinazoline) were applied. A distinct group of hybrids comprises the molecules built with natural compounds: Resveratrol, curcumin, coumarin, and oleanolic acid. In this review, we present the studies on bioactive hybrid molecules of a well-known tubulin polymerization inhibitor, combretastatin A-4 and its analogs with other pharmacologically active entities. The mechanism of anticancer activity of selected hybrids is discussed considering the structure-activity relationship. MDPI 2019-03-14 /pmc/articles/PMC6471163/ /pubmed/30875859 http://dx.doi.org/10.3390/ijms20061300 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Piekuś-Słomka, Natalia
Mikstacka, Renata
Ronowicz, Joanna
Sobiak, Stanisław
Hybrid cis-stilbene Molecules: Novel Anticancer Agents
title Hybrid cis-stilbene Molecules: Novel Anticancer Agents
title_full Hybrid cis-stilbene Molecules: Novel Anticancer Agents
title_fullStr Hybrid cis-stilbene Molecules: Novel Anticancer Agents
title_full_unstemmed Hybrid cis-stilbene Molecules: Novel Anticancer Agents
title_short Hybrid cis-stilbene Molecules: Novel Anticancer Agents
title_sort hybrid cis-stilbene molecules: novel anticancer agents
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471163/
https://www.ncbi.nlm.nih.gov/pubmed/30875859
http://dx.doi.org/10.3390/ijms20061300
work_keys_str_mv AT piekussłomkanatalia hybridcisstilbenemoleculesnovelanticanceragents
AT mikstackarenata hybridcisstilbenemoleculesnovelanticanceragents
AT ronowiczjoanna hybridcisstilbenemoleculesnovelanticanceragents
AT sobiakstanisław hybridcisstilbenemoleculesnovelanticanceragents